Exploration of the mechanism of salvianolic acid for injection against ischemic stroke: a research based on computational prediction and experimental validation

File Description SizeFormat 
Li FRONTPHARM 2022 Salvianolic Acid.pdfPublished version2.26 MBAdobe PDFView/Open
Title: Exploration of the mechanism of salvianolic acid for injection against ischemic stroke: a research based on computational prediction and experimental validation
Authors: Li, X
Guo, K
Zhang, R
Wang, W
Sun, H
Yagüe, E
Hu, Y
Item Type: Journal Article
Abstract: Ischemic stroke (IS) is an acute neurological injury that occurs when a vessel supplying blood to the brain is obstructed, which is a leading cause of death and disability. Salvia miltiorrhiza has been used in the treatment of cardiovascular and cerebrovascular diseases for over thousands of years due to its effect activating blood circulation and dissipating blood stasis. However, the herbal preparation is chemically complex and the diversity of potential targets makes difficult to determine its mechanism of action. To gain insight into its mechanism of action, we analyzed “Salvianolic acid for injection” (SAFI), a traditional Chinese herbal medicine with anti-IS effects, using computational systems pharmacology. The potential targets of SAFI, obtained from literature mining and database searches, were compared with IS-associated genes, giving 38 common genes that were related with pathways involved in inflammatory response. This suggests that SAFI might function as an anti-inflammatory agent. Two genes associated with inflammation (PTGS1 and PTGS2), which were inhibited by SAFI, were preliminarily validated in vitro. The results showed that SAFI inhibited PTGS1 and PTGS2 activity in a dose-dependent manner and inhibited the production of prostaglandin E2 induced by lipopolysaccharide in RAW264.7 macrophages and BV-2 microglia. This approach reveals the possible pharmacological mechanism of SAFI acting on IS, and also provides a feasible way to elucidate the mechanism of traditional Chinese medicine (TCM).
Issue Date: 25-May-2022
Date of Acceptance: 21-Apr-2022
URI: http://hdl.handle.net/10044/1/97141
DOI: 10.3389/fphar.2022.894427
ISSN: 1663-9812
Publisher: Frontiers Media
Start Page: 1
End Page: 13
Journal / Book Title: Frontiers in Pharmacology
Volume: 13
Copyright Statement: © 2022 Li, Guo, Zhang, Wang, Sun, Yagüe and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Keywords: 1115 Pharmacology and Pharmaceutical Sciences
Publication Status: Published
Online Publication Date: 2022-05-25
Appears in Collections:Department of Surgery and Cancer



This item is licensed under a Creative Commons License Creative Commons